New drug BIVV020 shows promise for chronic ITP in small trial
NCT ID NCT04669600
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2a trial tested the drug BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. The main goal was to see if BIVV020 could help maintain a safe platelet count over time and reduce the need for emergency treatments. The study was small and open-label, meaning everyone knew they were getting the drug, so results are preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BIVV020 (SAR445088)
What this could lead to
If successful, BIVV020 could offer a new treatment option for people with chronic immune thrombocytopenia (ITP) to help maintain safe platelet levels.
What could go wrong
This was a very small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA (ITP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2030002
Ostrava - Poruba, 70852, Czechia
-
Investigational Site Number :2760001
Essen, 45147, Germany
-
Investigational Site Number :5280001
Leiden, 2333 ZA, Netherlands
-
Investigational Site Number :7240001
Palma de Mallorca, 07120, Spain
-
Investigational Site Number :7240002
A Coruña, A Coruña [La Coruña], 15006, Spain
-
Investigational Site Number :7240003
Seville, 41013, Spain
-
Investigational Site Number :8260002
London, London, City of, W12 0HS, United Kingdom
-
Investigational Site Number :8400001
Washington D.C., District of Columbia, 20007, United States
-
Investigational Site Number :8400002
Tamarac, Florida, 33321, United States